Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E
Formáid:	Journal article
Foilsithe / Cruthaithe:	BioMed Central 2018

Míreanna comhchosúla

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
de réir: Philip Helliwell, et al.
Foilsithe / Cruthaithe: (2018-10-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
de réir: Helliwell, P, et al.
Foilsithe / Cruthaithe: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
de réir: Nash, P, et al.
Foilsithe / Cruthaithe: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
de réir: Nash, P, et al.
Foilsithe / Cruthaithe: (2018)

Janus kinase inhibitors in the treatment of psoriatic arthritis
de réir: E. Yu. Loginova, et al.
Foilsithe / Cruthaithe: (2022-02-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
de réir: Tucker, L, et al.
Foilsithe / Cruthaithe: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
de réir: Miao Chen, et al.
Foilsithe / Cruthaithe: (2020-04-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
de réir: Lubrano, E, et al.
Foilsithe / Cruthaithe: (2019)

Current concepts and unmet needs in psoriatic arthritis
de réir: Mahmood, F, et al.
Foilsithe / Cruthaithe: (2017)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
de réir: Nash, P, et al.
Foilsithe / Cruthaithe: (2018)

Remission in psoriatic arthritis—where are we now?
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2017)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
de réir: P.S. Helliwell
Foilsithe / Cruthaithe: (2011-09-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
de réir: Ennio Lubrano, et al.
Foilsithe / Cruthaithe: (2019-08-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2024)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2021)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2018)

Best-practice indicators in Psoriatic disease care
de réir: Helliwell, P, et al.
Foilsithe / Cruthaithe: (2019)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2016)

What should be the primary target of "treat to target" in psoriatic arthritis?
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
de réir: Peter Nash, et al.
Foilsithe / Cruthaithe: (2018-11-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
de réir: Mease, P, et al.
Foilsithe / Cruthaithe: (2018)

Psoriatic arthritis
de réir: FitzGerald, O, et al.
Foilsithe / Cruthaithe: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
de réir: Laura C. Coates, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
de réir: Jiao Wang, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
de réir: Soriano, ER, et al.
Foilsithe / Cruthaithe: (2023)

Psoriatic Arthritis: A Review
de réir: Farrouq Mahmood, et al.
Foilsithe / Cruthaithe: (2016-07-01)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
de réir: Helliwell, PS, et al.
Foilsithe / Cruthaithe: (2021)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
de réir: E. E. Gubar, et al.
Foilsithe / Cruthaithe: (2021-10-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
de réir: Laure Gossec, et al.
Foilsithe / Cruthaithe: (2024-02-01)

How should we define disease and outcomes in axial psoriatic arthritis?
de réir: Coates, LC
Foilsithe / Cruthaithe: (2021)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
de réir: Vivekanantham, A, et al.
Foilsithe / Cruthaithe: (2024)

Measuring outcomes in psoriatic arthritis
de réir: Ogdie, A, et al.
Foilsithe / Cruthaithe: (2020)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
de réir: Vishal R. Tandon, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
de réir: Braun, J, et al.
Foilsithe / Cruthaithe: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
de réir: Philip J. Mease, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
de réir: Yazji, SM, et al.
Foilsithe / Cruthaithe: (2025)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
de réir: Nash, P, et al.
Foilsithe / Cruthaithe: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2022)